by The neutralizing antibody market has been gaining significant traction over the recent past owing to the increasing prevalence of various infectious diseases including COVID 19, influenza, hepatitis, HIV/AIDS, etc. across the globe. Neutralizing antibodies play a vital role in protecting against pathogen invasion by binding to antigens expressed on the surface of pathogens and preventing them from entering and infecting host cells. With the outbreak of COVID 19 pandemic, there has been immense focus on developing monoclonal antibody therapeutics that can neutralize the SARS CoV 2 virus. Some of the monoclonal antibody therapies that have received emergency use authorization for treatment of mild to moderate COVID 19 include Bamlanivimab, Casirivimab plus Imdevimab from Regeneron and Sotrovimab from Vir Biotechnology/GlaxoSmithKline.
The global neutralizing antibody market is estimated to be valued at US$ 1.87 Billion in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the neutralizing antibody market is the increasing investments by market players as well as government organizations in developing novel neutralizing antibodies for infectious diseases. For instance, in December 2021, Vir Biotechnology announced funding of US$ 300 million by the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support the development of novel neutralizing monoclonal antibodies for prevention and treatment of SARS-CoV-2 infections. Similarly, several biopharmaceutical companies are engaged in developing neutralizing monoclonal antibodies against influenza, HIV/AIDS, hepatitis viruses, etc. Growing adoption of advanced antibody discovery and engineering technologies such as phage display and rational drug design is also facilitating development of highly potent and effective neutralizing antibodies.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as considerable capital investments are required for R&D and production facilities. However, new players can leverage strategic partnerships and alliances to enter the market.
Bargaining power of buyers: The bargaining power of buyers is moderate as neutralizing antibodies have applications across several disease areas. However, established buyers prefer dealing with reputed suppliers for quality and reliability.
Bargaining power of suppliers: The bargaining power of suppliers is high given the specialized expertise required for manufacturing neutralizing antibodies. Suppliers can benefit from long-term contracts with buyers.
Threat of new substitutes: Threat of substitutes is low as neutralizing antibodies have few substitutes for applications like viral neutralization assays. However, alternatives like inhibitor molecules pose a medium threat.
Competitive rivalry: Competition is high among key players like Mohawk to expand their product portfolios and global footprint.
Key Takeaways
Global Neutralizing Antibody Market is expected to witness high growth. Global Neutralizing Antibody Market Size is estimated to be valued at US$ 1.87 Billion in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2031.
Regional analysis comprised Regional analysis related content: North America dominates the market currently due to major biopharma companies and research organizations focused on developing COVID-19 vaccines. Asia Pacific is anticipated to grow at the fastest pace during the forecast period.
Key players related content comprises: Key players operating in the Neutralizing Antibody Market include Mohawk. Mohawk offers a comprehensive portfolio of neutralizing antibodies for viral diseases such as hepatitis B, rabies, influenza, and other infectious diseases.
